Review of NVP and HG and Early Pharmacotherapeutic Intervention
NVP occurs in 50–90% of pregnancies, making it a common medical condition in pregnancy. Women present differently with any combination of signs and symptoms. It is appropriate to take the pregnancy-related versus nonpregnancy-related approach when determining the cause of nausea and vomiting but oth...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Obstetrics and Gynecology International |
| Online Access: | http://dx.doi.org/10.1155/2012/252676 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554281963618304 |
|---|---|
| author | Shannon M. Clark Maged M. Costantine Gary D. V. Hankins |
| author_facet | Shannon M. Clark Maged M. Costantine Gary D. V. Hankins |
| author_sort | Shannon M. Clark |
| collection | DOAJ |
| description | NVP occurs in 50–90% of pregnancies, making it a common medical condition in pregnancy. Women present differently with any combination of signs and symptoms. It is appropriate to take the pregnancy-related versus nonpregnancy-related approach when determining the cause of nausea and vomiting but other causes should be considered. The most common etiologies for NVP include the hormonal changes associated with pregnancy, the physiologic changes in the gastrointestinal tract, and a genetic predisposition. Up to 10% of women will require pharmacotherapy to treat the symptoms of NVP despite conservative measures. ACOG currently recommends that a combination of oral pyridoxine hydrochloride and doxylamine succinate be used as first-line treatment for NVP if pyridoxine monotherapy does not relieve symptoms. A review of NVP and early pharmacotherapeutic management is presented due to the fact that NVP is largely undertreated, and investigations into the safe and effective pharmacotherapies available to treat NVP are lacking. |
| format | Article |
| id | doaj-art-577646b17fa34494b9d885f009597403 |
| institution | Kabale University |
| issn | 1687-9589 1687-9597 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Obstetrics and Gynecology International |
| spelling | doaj-art-577646b17fa34494b9d885f0095974032025-02-03T05:51:53ZengWileyObstetrics and Gynecology International1687-95891687-95972012-01-01201210.1155/2012/252676252676Review of NVP and HG and Early Pharmacotherapeutic InterventionShannon M. Clark0Maged M. Costantine1Gary D. V. Hankins2Division of MFM, Department of Obstetrics and Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USADivision of MFM, Department of Obstetrics and Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USADivision of MFM, Department of Obstetrics and Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USANVP occurs in 50–90% of pregnancies, making it a common medical condition in pregnancy. Women present differently with any combination of signs and symptoms. It is appropriate to take the pregnancy-related versus nonpregnancy-related approach when determining the cause of nausea and vomiting but other causes should be considered. The most common etiologies for NVP include the hormonal changes associated with pregnancy, the physiologic changes in the gastrointestinal tract, and a genetic predisposition. Up to 10% of women will require pharmacotherapy to treat the symptoms of NVP despite conservative measures. ACOG currently recommends that a combination of oral pyridoxine hydrochloride and doxylamine succinate be used as first-line treatment for NVP if pyridoxine monotherapy does not relieve symptoms. A review of NVP and early pharmacotherapeutic management is presented due to the fact that NVP is largely undertreated, and investigations into the safe and effective pharmacotherapies available to treat NVP are lacking.http://dx.doi.org/10.1155/2012/252676 |
| spellingShingle | Shannon M. Clark Maged M. Costantine Gary D. V. Hankins Review of NVP and HG and Early Pharmacotherapeutic Intervention Obstetrics and Gynecology International |
| title | Review of NVP and HG and Early Pharmacotherapeutic Intervention |
| title_full | Review of NVP and HG and Early Pharmacotherapeutic Intervention |
| title_fullStr | Review of NVP and HG and Early Pharmacotherapeutic Intervention |
| title_full_unstemmed | Review of NVP and HG and Early Pharmacotherapeutic Intervention |
| title_short | Review of NVP and HG and Early Pharmacotherapeutic Intervention |
| title_sort | review of nvp and hg and early pharmacotherapeutic intervention |
| url | http://dx.doi.org/10.1155/2012/252676 |
| work_keys_str_mv | AT shannonmclark reviewofnvpandhgandearlypharmacotherapeuticintervention AT magedmcostantine reviewofnvpandhgandearlypharmacotherapeuticintervention AT garydvhankins reviewofnvpandhgandearlypharmacotherapeuticintervention |